Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of “Hold” by Analysts

Bausch Health Companies Inc. (NYSE:BHC) has been given an average rating of “Hold” by the seven research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.75.

A number of analysts have commented on BHC shares. Royal Bank of Canada boosted their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research note on Friday, November 1st. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Bausch Health Companies Stock Up 1.3 %

NYSE:BHC opened at $7.58 on Thursday. The company has a fifty day moving average of $8.03 and a 200-day moving average of $7.44. The firm has a market capitalization of $2.74 billion, a P/E ratio of -15.79 and a beta of 0.69. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 EPS. On average, analysts anticipate that Bausch Health Companies will post 3.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC purchased a new position in shares of Bausch Health Companies in the 2nd quarter worth about $35,000. MQS Management LLC purchased a new position in shares of Bausch Health Companies in the 2nd quarter worth about $71,000. Kendall Capital Management purchased a new position in shares of Bausch Health Companies in the 2nd quarter worth about $87,000. Brown Brothers Harriman & Co. purchased a new stake in Bausch Health Companies during the second quarter valued at about $109,000. Finally, International Assets Investment Management LLC purchased a new stake in Bausch Health Companies during the third quarter valued at about $1,910,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.